Table 1 Patient characteristics. Clinical characteristics of the study cohort. P: primary, M: metastasis, hep: hepatic, os: osseous, M.r.s.: Musculus rectus superior, SST: somatostatin analogue, TACE: transarterial chemoembolization, PRRT: Peptide Receptor Radionuclide Therapy, Tem: temozolomide, Cap: capecitabine, Ox: oxaliplatin, Bev: Bevacizumab, SD: stable disease.
From: Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors
PAT ID | SEX | AGE | G | KI67 P | KI67 M | T | N | M | L | V | PN | R | THERAPY | STATUS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 60 | G1 | <2% | <2% | 3 | 1 | hep. | 1 | 0 | 1 | 0 | SST -> SD | alive |
2 | M | 57 | G2 | 10% | 10% | 3 | 0 | hep., os. | 1 | 1 | 1 | 1 | SST/TACE/PRRT -> SD | alive |
3 | F | 67 | G2 | 10–15% | 10–15% | 4 | 1 | hep. | 1 | 1 | 1 | 0 | SST ->SST/TACE ->PRRT -> TACE/SST | alive |
4 | M | 68 | G2 | 4–5% | <2% | 3 | 0 | hep. | 1 | 1 | 1 | 0 | SST, Everolimus, Tem/Cap, Cap/Ox/Bev | deceased |
5 | M | 52 | G1 | <2% | 5% | 2 | 1 | hep., os., M.r.s. | 1 | 1 | 0 | 0 | SST | deceased |
